Topological data analysis identifies distinct biomarker phenotypes during the 'inflammatory' phase
 of COVID-19.

3

4	Authors: Paul W. Blair, MD ^{1,2} *, Joost Brandsma, PhD ¹ , Josh Chenoweth, PhD ¹ , Stephanie A. Richard,
5	PhD ³ , Nusrat J. Epsi, PhD ^{1,3} , Rittal Mehta, MSc ¹ , Deborah Striegel, PhD ¹ , Emily G. Clemens, MFA ² ,
6	David A. Lindholm, MD ^{4,5} , Ryan C. Maves, MD ^{3,6,7} ; Derek T. Larson, DO ⁸ ; Katrin Mende, MD ³ , Rhonda
7	E. Colombo, MD ^{1,3,9} , Anuradha Ganesan, MD ^{1,3,10} , Tahaniyat Lalani, MD ^{3,11} , Christopher J Colombo,
8	MD ^{3,9} , Allison A. Malloy, MD ¹² , Andrew L. Snow, PhD ¹³ , Kevin L. Schully, PhD ¹⁴ , Charlotte Lanteri,
9	PhD ³ , Mark P. Simons, PhD ^{3,1} , John S. Dumler, MD, PhD ² , David Tribble, MD ^{1,3} , Timothy Burgess,
10	MD ⁴ , Simon Pollett, MBBS ^{1,3} , Brian K. Agan, MD ^{1,3} , Danielle V. Clark, PhD ¹ and the EPICC COVID-19
11	Cohort Study Group.**
12	

13 Affiliation: ¹The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. ,

14 Bethesda, MD; ²Department of Pathology, Uniformed Services University, Bethesda, MD; ³Infectious

15 Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed

16 Services University, Bethesda, MD; ⁴Department of Medicine, Uniformed Services University of the

17 Health Sciences, Bethesda, MD; ⁵Brooke Army Medical Center, Joint Base San Antonio-Ft Sam Houston,

18 TX; ⁶Departments of Internal Medicine and Anesthesiology, Wake Forest School of Medicine, Winston-

19 Salem, North Carolina; ⁷Naval Medical Center, San Diego, California; ⁸Fort Belvoir Community Hospital,

20 Fort Belvoir, VA; ⁹Madigan Army Medical Center, Joint Base Lewis-McChord, WA; ¹⁰Walter Reed

21 National Military Medical Center, Bethesda, MD;¹¹Naval Medical Center Portsmouth, Portsmouth, VA;

22 ¹²Department of Pediatrics, Uniformed Services University, Bethesda, MD; ¹³Department of

23 Pharmacology & Molecular Therapeutics, Uniformed Services University, Bethesda, MD; ¹⁴Biological

24 Defense Research Directorate, Naval Medical Research Center-Frederick, Ft. Detrick, MD.

25	*Corresponding Author: Paul W. Blair, MD MSPH MHS. Henry M. Jackson Foundation for the
26	Advancement of Military Medicine. 6720A Rockledge Dr, Bethesda, MD 20817. E-mail: pblair@aceso-
27	sepsis.org
28	Reprints: Reprints are not being ordered for this manuscript.
29	Performance institution: Henry M. Jackson Foundation for the Advancement of Military Medicine
30	Funding: This project has been funded by the National Institute of Allergy and Infectious Diseases,
31	National Institutes of Health, under Inter-Agency Agreement Y1-AI-5072, the Defense Health Program,
32	U.S. DoD, under award HU0001190002, and the Defense Health Agency, U.S. DoD, under awards
33	HU00012020070 and W911QY-20-9-0006. Biomarker assay reagents and analysis support was
34	provided by JPEO W911QY-20-9-0004 (2020 OTA).
35 36	
37	Word count: 2,995
38	Abstract Word count: 225
39 40 41 42 43 44 45 46 47 48 49 51 52 53 54 55 57 58 9 60 61	

62 Abstract:

- 63 OBJECTIVES: The relationships between baseline clinical phenotypes and the cytokine milieu of the peak
- 64 'inflammatory' phase of coronavirus 2019 (COVID-19) are not yet well understood. We used Topological
- 65 Data Analysis (TDA), a dimensionality reduction technique to identify patterns of inflammation associated
- 66 with COVID-19 severity and clinical characteristics.
- 67 DESIGN: Exploratory analysis from a multi-center prospective cohort study.
- 68 SETTING: Eight military hospitals across the United States between April 2020 and January 2021.
- 69 PATIENTS: Adult (≥18 years of age) SARS-CoV-2 positive inpatient and outpatient participants were
- rolled with plasma samples selected from the putative 'inflammatory' phase of COVID-19, defined as
- 71 15-28 days post symptom onset.
- 72 INTERVENTIONS: None.
- 73 MEASUREMENTS AND MAIN RESULTS: Concentrations of 12 inflammatory protein biomarkers were
- 74 measured using a broad dynamic range immunoassay. TDA identified 3 distinct inflammatory protein
- 75 expression clusters. Peak severity (outpatient, hospitalized, ICU admission or death), Charlson Comorbidity
- 76 Index (CCI), and body mass index (BMI) were evaluated with logistic regression for associations with each
- 77 cluster. The study population (n=129, 33.3% female, median 41.3 years of age) included 77 outpatient, 31
- 78 inpatient, 16 ICU-level, and 5 fatal cases. Three distinct clusters were found that differed by peak disease
- 79 severity (p <0.001), age (p <0.001), BMI (p<0.001), and CCI (p=0.001).
- CONCLUSIONS: Exploratory clustering methods can stratify heterogeneous patient populations and
 identify distinct inflammation patterns associated with comorbid disease, obesity, and severe illness due to
 COVID-19.
- 83 KEY WORDS: COVID-19; SARS-CoV-2; Topological Data Analysis; Coronavirus Infections /
- 84 immunology, Cytokines / analysis
- 85
- 86
- 87

88 Background

89 While clinical risk factors for coronavirus disease 2019 (COVID-19) severity have been described, 90 mechanisms of inflammation associated with these baseline clinical features are less understood (1). SARS-91 CoV-2 infections range from asymptomatic to fatal illness. This spectrum is associated with host risk factors 92 such as age and chronic noncommunicable disease (NCD), including obesity and cardiovascular disease 93 (2). However, the pathways from host factors to COVID-19 severity and sequelae are largely unknown. 94 Given the heterogeneity of COVID-19 severity and a growing immunomodulatory treatment 95 armamentarium (2, 3), pathologic inflammation patterns and their association with comorbidities need to 96 be identified to optimize treatment selection.

97

98 COVID-19 severity and inflammation occur in three phases: acute, inflammatory, and late phases of illness. 99 Peak severity and peak inflammatory biomarkers generally occur after two weeks of illness (15 to 28 days 100 after symptom onset) during the inflammatory phase (4, 5). While inflammation may subside in mild cases, 101 persistently high proinflammatory cytokines have been noted in more severe cases during this period. This 102 time window of heightened immune response may be best suited to elucidate the relationship between host 103 factors and severe COVID-19. In silico stratification of host-biomarker profiles using exploratory clustering 104 and machine learning analyses has the potential to identify distinct phenotypes associated with disease 105 severity, which in turn can lead to discovery of personalized treatment approaches.

106

Herein we define inflammatory host-biomarker phenotypes of COVID-19 identified by Topological Data Analysis (TDA) and their associated comorbid conditions and disease severity. TDA is a multivariate pattern analytical tool that uses an unsupervised approach to dimensionality reduction and data visualization (6). TDA can be used to identify biomarker patterns and phenotype-biomarker relationships (7-9). TDA has been demonstrated to identify patient subgroups that would benefit from personalized interventions for heterogenous diseases such as cancer care and primary ciliary dyskinesia (6, 8). We hypothesized that the network approach of TDA clustering would identify unique inflammation phenotype patterns associated with severity, demographics, and co-morbid conditions known to predispose patients to worse outcomes during SARS-CoV-2 infection (4). Our analysis focused on samples collected during the inflammatory phase from an observational cohort of participants with mild to severe COVID-19 at military treatment facilities. Inflammatory biomarkers were selected from prior unpublished non-COVID-19 sepsis TDA analyses (10) and from clinical use (11). We sought to demonstrate that this analytical approach can help discern inflammatory patterns to find possible treatment targets, as well as serve as a tool to understand baseline host factors and severe COVID-19.

121

122 Methods

123 Participants were enrolled in a prospective, multi-center COVID-19 cohort under the Epidemiology, 124 Immunology, and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential 125 (EPICC) protocol, at 8 military treatment facilities (Brooke Army Medical Center, San Antonio, TX; Fort 126 Belvoir Community Hospital, Fort Belvoir, VA; Madigan Army Medical Center, Joint Base Lewis-127 McChord, WA; Naval Medical Center Portsmouth, Portsmouth, VA; Naval Medical Center San Diego, San 128 Diego, CA; Tripler Army Medical Center, Honolulu, HI; William Beaumont Army Medical Center, El 129 Paso, TX; Walter Reed National Military Medical Center, Bethesda, MD) between April 2020 and January 130 2021 (12). The protocol was approved by the Uniformed Services University Institutional Review Board 131 (IDCRP-085)(13). All patients provided written informed consent. EPICC study enrollment included 132 subjects \geq 18 years of age with laboratory-confirmed or suspected SARS-CoV-2 infection seeking inpatient 133 or outpatient medical care. Following consent, demographic, comorbidity, and illness data were collected 134 through participant interviews and a review of the participant's electronic medical record or using 135 participant completed surveys implemented in November 2020. Subjects with a positive clinical SARS-136 CoV-2 RT-PCR result and plasma samples collected were included in this analysis. Results of well-137 described (14) COVID-19 clinical biomarkers CRP, ferritin, and IL-6, were explored from 249 participants 138 with plasma collected 0-29 days post symptom onset (dpso) to determine if the longitudinal inflammatory 139 biomarker LOESS (locally estimated scatterplot smoothing) curve peaked between 14 to 28 days per

previously published phases of illness framework for studying COVID-19 (Supplementary Figure S1) (4).
These trends were consistent with the literature, and, accordingly, the TDA was restricted to the 129
participants with samples collected during the inflammatory phase defined as 15-28 dpso. Receipt of
baricitinib, tocilizumab, hydroxychloroquine, or systemic steroids (equivalent to prednisone 10mg daily or
above) at the time of blood collection was determined through the electronic medical record or participant
surveys.

146

147 Plasma samples were prospectively collected after enrollment as previously described (13). Venous whole 148 blood samples were centrifuged for 10 minutes at 1500 g and collected plasma was stored at -80°C. A 149 panel of 12 inflammatory proteins were measured in the plasma samples using the high dynamic range 150 automated enzyme-linked immunosorbent assay Ella microfluidic analyzer (ProteinSimple, San Jose, 151 California, USA). The panel included: IL-6, CXCL10, IL-1RA, D-dimer, procalcitonin, ferritin, VEGF-A, 152 IL-5, soluble receptor for advanced glycation end-product (RAGE), TNFR1, IFN- γ , and C-reactive protein 153 (CRP). This panel was selected to include analytes in clinical use for prognostication (i.e., CRP, 154 procalcitonin, ferritin, and D-dimer)(11), based on prior COVID-19 literature (i.e., IL-6, IFN- γ and 155 CXCL10) (15), and identified to be representative of prior TDA-based non-COVID-19 sepsis clusters (i.e., 156 IL-1RA, VEGF-A, IL-5, RAGE, and TNFR1) (10, 16). All protein concentrations were log₁₀-transformed 157 and normalized for site-to-site variation using the R package SVA ComBat (17). A small number (1.6%) of 158 missing values were imputed using a k-nearest neighbor model, and out-of-range values were imputed using 159 either the lowest or highest measured value within range of the Ella platform. Correlation between analytes 160 was explored with a principal component analysis and determining the Spearman's correlation coefficients. 161 For some subjects, multiple samples were available. In such cases, the sample with the highest coefficient 162 of variation across all analytes was retained to incorporate the largest degree of relative variability at that 163 time point (18).

165 Protein expression networks were generated solely using biomarkers levels with the TDA "Mapper" algorithm using the EurekaAI platform (SymphonyAI, Los Altos, CA, USA)(7, 19, 20). TDA networks 166 167 were generated for a range of resolution settings to examine the persistence of subject clusters and their 168 interrelatedness. Peaked severity (outpatient, hospitalized, ICU-level or death) color gradients were 169 overlaid on identified clusters. Levels of the individual proteins in each TDA group were summarized in a 170 series of boxplots (*R* package "ggplot2" v3.3.5). Backward selection stepwise logistic regression using a 171 Bernoulli-adjusted significance level of 0.0042 (i.e., 0.05/12) was used to identify which proteins were up-172 or downregulated within each cluster. While TDA clusters will inherently have different biomarker levels, 173 this was performed to simplify inference about representative biomarkers and for future validation in 174 external cohorts. A sensitivity analysis was performed adjusting for peak severity to determine the effect 175 of covariate selection. An additional sensitivity analysis was performed excluding participants receiving 176 systemic steroids.

177

178 Summary statistics were calculated for the TDA clusters, comparing baseline demographics (e.g., sex, age, 179 race, ethnicity, selected medical comorbidities), days post symptom onset, peak severity, steroid use, and 180 the inflammatory biomarkers by clusters using either Chi-square (categorical values), Fisher exact 181 (categorical values), or Mann-Whitney U tests (continuous values). Charlson Comorbidity Index (CCI) and 182 body mass index (BMI) values were divided into score-based categories (i.e., CCI: 0, 1-2, 3-4, or 5+; BMI: 183 <30, 30-39.9, or \geq 40 kg/m²) to describe the prevalence of comorbid conditions by cluster on a bar plot but 184 were otherwise treated as continuous values. BMI values were not available from 6.2% of the cohort. Peak 185 severity was categorized for each participant (outpatient, non-ICU [intensive care unit] inpatient, and ICU 186 or death). Multivariable logistic regression adjusting for peak severity was used to identify associations 187 between each TDA cluster and BMI or CCI at a significance level of 0.05. All statistical analyses were 188 performed in Stata (version 15.0; StataCorp LLC, College Station, TX, USA) and R version 4.0.2 (21)

189

190 **Results**

191 Biomarkers CRP, IL-6, and ferritin were stratified by severity and explored for the 249 participants in the EPICC cohort between 0-28 dpso using a scatter plot with LOESS (locally estimated scatterplot smoothing) 192 193 curves. This demonstrated average cytokines peaked or remained elevated during the described 194 inflammatory phase (15-28 dpso) among ICU-level or fatal courses of illness (Supplementary Figure S1). 195 Based on these findings and the inflammatory phase literature, we restricted our analysis to 129 participants 196 (66.7% male, median 41.3 years of age) including 77 outpatient, 31 inpatient, 16 ICU-level, and 5 fatal 197 cases (Table 1) between 15 to 28 days of illness. Correlation along a PCA axis was observed among 198 procalcitonin, TNFR1, IL-6, CRP, and IL-1RA while RAGE, IFN-γ, IL-5, and VEGF-A were less 199 correlated with the other analytes. Additionally, variance increased with each level of peak severity 200 (Supplementary Figure S2). These results supported the additive information provided by the 12 protein 201 analytes, and TDA was performed. Interestingly, 3 distinct inflammatory proteins clusters, labeled Cluster 202 1, Cluster 2, and Cluster 3 (Figure 1; Supplementary Figure S3), were consistently identified using TDA.

203

204 Age differed significantly between TDA clusters (p<0.001). Participants from TDA Clusters 2 (median 205 37.1 years of age; IQR, 28.1 to 50.0) and 3 (median 36.3 years of age; IQR, 24.6 to 55.2) were younger 206 than in Cluster 1 (median 51.8 years of age; IQR, 37.3 to 65.0) (Table 1). The prevalence of male gender 207 was similar among Cluster 1 (62.0%, n=31), Cluster 2 (64.1%, n=41), and the general cohort (66.7%), but 208 cluster 3 was predominantly male (93.3%, n=14). The median time from symptom onset to sample 209 collection was 21 days (IQR 18 to 25) and did not differ between clusters (Table 1). Peak disease severity, 210 as categorized by hospitalization status, was also found to differ significantly among the TDA clusters 211 (p<0.001). Cluster 1 had the highest prevalence of severe COVID-19, comprising 66.0% (n=33) 212 hospitalized participants, compared to 46.7% (n=7) hospitalized participants in Cluster 3, and 18.8% (n=12) 213 hospitalized participants in Cluster 2 (Figure 2, Table 1). All fatal cases (n=5) were in Cluster 1. No 214 individuals had received baricitinib or tocilizumab, and hydroxychloroquine use was limited to 2 215 individuals in Cluster 1. Receipt of systemic steroids at the time of blood collection was limited to 5 216 participants in Cluster 1 (10.0%; n=5).

217

The median CCI differed (p=0.009) among clusters ranging from 2 (IQR, 2 to 3) in Cluster 1 to 0 (IQR 0 218 219 to 0.5) in Cluster 2 and 0 (IQR, 0 to 1) in Cluster 3. Most participants in Cluster 2 (75.0%) and in Cluster 3 220 (73.3%) had a CCI of 0 compared to 38.0% of individuals in Cluster 1 (Figure 2). Additionally, median 221 BMI was higher in Cluster 1 (33.5 kg/m²; IQR, 29.0 to 37.0) compared to in Cluster 2 and Cluster 3, which 222 were the same (28.0 kg/m²; IOR, 25.0 to 31.0)(Table 1). After adjusting for peak severity using logistic 223 regression, participants with a higher BMI (OR: 1.1 per kg/m², p=0.002) and a higher CCI (OR: 1.3 for 224 each score increase, p=0.02) were more common in Cluster 1 compared to participants in Cluster 2 and 3 225 combined.

226

In summary, participants in Cluster 1 were more likely to be older, have higher BMI and more comorbidities, and have more severe disease, whereas participants in Cluster 2 were more likely to be younger, have lower BMI and comorbidities, and have mild illness (Figure 2). Cluster 3 was predominantly composed of younger adult predominantly male participants, without comorbid conditions, among whom almost half (7 of 15) were hospitalized.

232

233 The distributions of each analyte were different across clusters using a chi-squared test, except for IL-5 and 234 IFN-γ which had a similar distribution (Table 2). Certain biomarkers including CRP, IL-6, IL-1RA, D-235 dimer, TNFR1, and VEGF-A were more elevated in Cluster 1 (older participants with higher severity) 236 compared to Clusters 2 and 3 (Table 2; Figure 3; Supplementary Figure 4). RAGE was lower in Cluster 1 237 compared to Clusters 2 or 3 and IFN-y was lower in Cluster 1 compared to Cluster 2 (Figure 3; 238 Supplementary Figure 4). Cluster 3, a young cluster with moderate severity, was found to have higher 239 ferritin, procalcitonin, and CXCL10, and lower VEGF-A compared to Cluster 2, a similarly young cluster 240 with mild illness.

242 Stepwise regression, both unadjusted and adjusted for peak severity, was used to identify which analytes 243 were most characteristic of each TDA cluster (Supplementary Table S1.). The distinguishing biomarker of 244 Cluster 1 were relatively high IL-1RA and low RAGE levels; these subjects had a high severity phenotype 245 compared to other clusters (Figure 3; Supplementary Figure 4; Supplementary Table S1.). Regardless of 246 peak severity, Cluster 2 was characterized by relatively low procalcitonin and high RAGE levels. Cluster 3 247 was characterized by low VEGF-A after peak severity adjustment (Figure 3; Supplementary Figure 4; 248 Supplementary Table S1.). When restricting the analysis to those not receiving steroids, the models were 249 qualitatively unchanged, and the same covariates were selected.

250

251 Discussion

252 We demonstrated that a multi-site prospective patient cohort can be stratified into three distinct 253 inflammatory profiles using 12 protein biomarkers from samples collected during the inflammatory phase 254 of COVID-19. TDA dimensionality reduction was able to identify biomarker patterns with differences in 255 both severity and comorbid conditions between cluster phenotypes. Combinations of biomarkers, 256 independent of clinical information, grouped participants into one of three distinct clusters: high COVID-257 19 severity, older, with comorbid conditions (Cluster 1); low severity, younger, less comorbid illness 258 (Cluster 2); and a moderate severity, younger, previously healthy, male-predominant group (Cluster 3). 259 This proof-of-concept study identifies potential use of TDA as a strategy to identify biomarker clusters 260 associated with the heterogeneity of COVID-19 clinical presentations. Whilst exploratory, this reveals 261 potential translational approaches to using host-biomarker stratification with advanced clustering and 262 network analytical techniques, such as TDA, to better understand what drives phenotypic differences in the 263 clinical presentation of COVID-19.

264

Patterns of inflammation observed for the different TDA clusters could suggest dysregulated pathways
associated with COVID-19 pathology. Cluster 1 was found to be the highest severity cluster with all fatal
cases and most ICU-level cases. This cluster contained distinctly more subjects with baseline comorbid

268 conditions and obesity as defined by BMI >30. Cluster 1 subjects had higher IL-1RA compared to Cluster 269 2 and 3, clusters represented by participants with less comorbid conditions. Consistent with this trend, prior 270 work has identified IL-1RA as a potential mediator between obesity and COVID-19 severity (22). 271 Interestingly, IFN- γ was lower and IL-6 higher in Cluster 1 compared to the Cluster 2 participants. This 272 pattern of an aberrant Th1 response has been previously identified to be associated with severe COVID-19 273 and potentially distinct from influenza infection (22). Cluster 1 aligned with baseline comorbid illnesses 274 known to be risk factors for severe COVID-19 with potentially distinct inflammatory cascade patterns 275 demonstrated.

276

277 Cluster 3 was unique in that it had a combination of low VEGF-A but had elevated ferritin and higher 278 prevalence of severe illness compared to Cluster 2, a mild illness cluster with comparable demographics. 279 While sample size is limited, 14 of 15 participants in Cluster 3 were male, suggestive of a biologic sex 280 difference in immune response among these previously healthy young men. Sex differences leading to 281 severe COVID-19 among men have been previously described with X-linked TLR7 deficiency(23, 24) 282 and on a larger scale with sex-related differences in innate and T-cell responses (25). A combination of 283 low VEGF-A and elevated ferritin may identify a unique inflammation subtype and merits further study 284 with external cohorts.

285

286 RAGE, a biomarker of acute lung injury (26), was found to have different distributions between clusters. 287 In contrast to prior research (27), RAGE levels appeared to be higher among the younger and relatively 288 milder COVID-19 severity Cluster 2 compared to Cluster 1. Compared to other clusters, RAGE was 289 elevated along with IFN- γ in the less symptomatic Cluster 2, but with lower acute phase reactants ferritin 290 and procalcitonin. The converse was true with Cluster 1 where lower levels of RAGE in individuals were 291 noted, along with elevated acute phase reactants (i.e., CRP, procalcitonin, and ferritin). This association 292 of lower RAGE with higher severity Clusters 1 and 3 contrasts with a direct association with COVID-19 293 mortality (28). However, our results may differ by accounting for biomarker patterns rather than

evaluating each biomarker in isolation. It is possible that RAGE could be an indicator of severity during
certain disease states but functioning as an adaptive anti-inflammatory protein in Cluster 2 during the
inflammatory phase. Soluble RAGE has been shown to reduce vascular injury in rodent models (29, 30)
and could be protective against vascular inflammation mediated the RAGE receptor (31). The
paradoxically inverse relationship observed between RAGE and these commonly used acute phase
reactants between the clusters could be useful for identification and stratification of individuals with
COVID-19.

301

302 While this study, to our knowledge, is the first to use an advanced dimensionality reduction approach to 303 understand relationships between biomarker patterns and clinical phenotypes during the inflammatory 304 phase of COVID-19, there are limitations worth noting. Samples were collected from April 2020 to 305 January 2021 and treatment practices and epidemiologic changes over time may have affected 306 inflammation patterns. Hence, we incorporated a sensitivity analysis excluding those that received 307 systemic steroids in Cluster 1 to aid in interpreting the findings. In addition, the sample size may limit our 308 ability to identify uncommon biomarker patterns and external validation is needed of patterns identified. 309 Additionally, regression was used to adjust for peak severity to identify biomarker and comorbid 310 condition associations with TDA clusters distinct from severity trajectory differences. While this is a 311 novel feature of this biomarker study, residual confounding related to peak severity remains possible. 312 Despite limitations, results presented here are hypothesis generating and should be evaluated further in 313 additional cohorts.

314

This approach constitutes an early exploratory step in identifying host biomarker patterns that may be leveraged for personalized interventions, and offers new insights for COVID19 prognosis, therapy, and prevention with techniques that could be extended to understanding other severe infections. Using analytes identified from our international sepsis cohort research(10), 3 biomarker clusters with different phenotypic associations were identified among those with heterogenous COVID-19 presentations. The application of 320 these biomarkers derived from non-COVID-19 severe infection research suggests that pathogen-agnostic 321 sepsis biomarkers could be identified for personalized approaches to triage of care or immunomodulation 322 strategies. Further validation of these markers and clustering algorithms with external cohorts could inform 323 point-of-care biomarker assay development to guide more individualized approaches to COVID-19 care.

324

325 Acknowledgements:

326 **We thank the members of the EPICC COVID-19 Cohort Study Group for their many contributions in

327 conducting the study and ensuring effective protocol operations. The following members were all closely

- involved with the design, implementation, and/or oversight of the study and have met group authorship
- 329 criteria for this manuscript:
- 330 Brooke Army Medical Center, Fort Sam Houston, TX: Col J. Cowden; LTC M. Darling; T. Merritt; CPT
- **331** T. Wellington
- 332 Fort Belvoir Community Hospital, Fort Belvoir, VA: A. Rutt
- 333 *Madigan Army Medical Center, Joint Base Lewis McChord, WA:* CAPT C. Conlon; COL P. Faestel;
- 334 COL C. Mount
- 335 Naval Medical Center Portsmouth, Portsmouth, VA: LCDR A. Smith; R. Tant; T. Warkentien
- 336 Naval Medical Center San Diego, San Diego, CA: CDR C. Berjohn; CAPT (Ret) G. Utz
- 337 Tripler Army Medical Center, Honolulu, HI: LTC C. Madar; C. Uyehara
- 338 Uniformed Services University of the Health Sciences, Bethesda, MD: K Chung; C. English; C. Fox; M.
- 339 Grother; COL P. Hickey; E. Laing; LTC J. Livezey; E. Parmelee; J. Rozman; M. Sanchez; A. Scher
- 340 United States Air Force School of Aerospace Medicine, Dayton, OH: Sgt T. Chao; R. Chapleau; A. Fries;
- 341 K. Reynolds
- 342 *Womack Army Medical Center, Fort Bragg, NC:* LTC D. Hostler; LTC J. Hostler; MAJ K. Lago; C.
- 343 Maldonado
- 344 William Beaumont Army Medical Center, El Paso, TX: MAJ T. Hunter; R. Mody; M. Wayman

345 Walter Reed National Military Medical Center, Bethesda, MD: MAJ N. Huprikar

- 347 The authors wish to also acknowledge all who have contributed to the EPICC COVID-19 study:
- 348 Brooke Army Medical Center, Fort Sam Houston, TX: Col J. Cowden; LTC M. Darling; S.
- 349 DeLeon; Maj D. Lindholm; LTC A. Markelz; K. Mende; S. Merritt; T. Merritt; LTC N. Turner; CPT T.
- 350 Wellington
- 351 Carl R. Darnall Army Medical Center, Fort Hood, TX: LTC S. Bazan; P.K Love
- 352 Fort Belvoir Community Hospital, Fort Belvoir, VA: N. Dimascio-Johnson; MAJ E. Ewers; LCDR K.
- 353 Gallagher; LCDR D. Larson; A. Rutt
- 354 Henry M. Jackson Foundation, Inc., Bethesda, MD: P. Blair; J. Chenoweth; D. Clark
- 355 Madigan Army Medical Center, Joint Base Lewis McChord, WA: S. Chambers; LTC C. J. Colombo; R.
- 356 Colombo; CAPT C. Conlon; CAPT K. Everson; COL P. Faestel; COL T. Ferguson; MAJ L. Gordon;
- 357 LTC S. Grogan; CAPT S. Lis; COL C. Mount; LTC D. Musfeldt; CPT D. Odineal; LTC M. Perreault; W.
- 358 Robb-McGrath; MAJ R. Sainato; C. Schofield; COL C. Skinner; M. Stein; MAJ M. Switzer; MAJ M.
- 359 Timlin; MAJ S. Wood
- 360 Naval Medical Center Portsmouth, Portsmouth, VA: S. Banks; R. Carpenter; L. Kim; CAPT
- 361 K. Kronmann; T. Lalani; LCDR T. Lee; LCDR A. Smith; R. Smith; R. Tant; T. Warkentien
- 362 Naval Medical Center San Diego, San Diego, CA: CDR C. Berjohn; S. Cammarata; N.
- 363 Kirkland; CAPT (Ret) R. Maves; CAPT (Ret) G. Utz
- 364 Tripler Army Medical Center, Honolulu, HI: S. Chi; LTC R. Flanagan; MAJ M. Jones; C. Lucas; LTC C.
- 365 Madar; K. Miyasato; C. Uyehara
- **366** Uniformed Services University of the Health Sciences, Bethesda, MD: B. Agan; L. Andronescu; A.
- 367 Austin; C. Broder; CAPT T. Burgess; C. Byrne; COL K Chung; J. Davies; C. English; N. Epsi; C.
- 368 Fox; M. Fritschlanski; M. Grother; A. Hadley; COL P. Hickey; E. Laing; LTC C. Lanteri; LTC
- J. Livezey; A. Malloy; R. Mohammed; C. Morales; P. Nwachukwu; C. Olsen; E. Parmelee; S. Pollett; S.

- 370 Richard; J. Rozman; J. Rusiecki; E. Samuels; M. Sanchez; A. Scher; CDR M. Simons; A.
- 371 Snow; K. Telu; D. Tribble; L. Ulomi
- 372 United States Air Force School of Medicine, Dayton, OH: Sgt T. Chao; R. Chapleau; A. Fries; C.
- 373 Harrington; S. Huntsberger; S. Purves; K. Reynolds; J. Rodriguez; C. Starr
- 374 Womack Army Medical Center, Fort Bragg, NC: B. Barton; LTC D. Hostler; LTC (Ret) J. Hostler; MAJ
- 375 K. Lago; C. Maldonado; J. Mehrer
- 376 William Beaumont Army Medical Center, El Paso, TX: MAJ T. Hunter; J. Mejia; R. Mody; R.
- 377 Resendez; P. Sandoval; M. Wayman
- 378 Walter Reed National Military Medical Center, Bethesda, MD: I. Barahona; A. Baya; A. Ganesan;
- 379 MAJ N. Huprikar; B. Johnson
- 380 Walter Reed Army Institute of Research, Silver Spring, MD: S. Peel
- 381
- 382 Conflicts of Interest: S. D. P., M.P.S., T. H. B, and D.R.T. report that the Uniformed Services University
- 383 (USU) Infectious Diseases Clinical Research Program (IDCRP), a US Department of Defense institution,
- and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc (HJF) were funded
- under a Cooperative Research and Development Agreement to conduct an unrelated phase III COVID-19
- 386 monoclonal antibody immunoprophylaxis trial sponsored by AstraZeneca. The HJF, in support of the USU
- 387 IDCRP, was funded by the Department of Defense Joint Program Executive Office for Chemical,
- Biological, Radiological, and Nuclear Defense to augment the conduct of an unrelated phase III vaccine
- trial sponsored by AstraZeneca. Both of these trials were part of the US Government COVID-19 response.
- **390** Neither is related to the work presented here.

391

392 <u>Disclaimer</u>: The contents of this article are the sole responsibility of the authors and do not necessarily
 393 reflect the views, assertions, opinions, or policies of the Henry M. Jackson Foundation for the Advancement
 394 of Military Medicine, Inc., the U.S. Department of Defense, the U.S. government, or any other government
 395 or agency. Mention of trade names, commercial products, or organizations does not imply endorsement by

396 the U.S. government. Some of the authors of this work are military service members or employees of the 397 U.S. government. This work was prepared as part of their official duties. Title 17 U.S.C. x105 provides that 398 "Copyright protection under this title is not available for any work of the United States government." Title 399 17 U.S.C. x101 defines a U.S. government work as a work prepared by a military service member or 400 employee of the U.S. government as part of that person's official duties. The investigators have adhered to 401 the policies for protection of human subjects as prescribed in 45 CFR 46. This research has been approved 402 the USU Institutional Review Board in compliance with all applicable federal regulations governing the 403 protection of human subjects.

404

405 References

406 1. Buicu AL, Cernea S, Benedek I, et al: Systemic Inflammation and COVID-19 Mortality in

407 Patients with Major Noncommunicable Diseases: Chronic Coronary Syndromes, Diabetes and Obesity. J

408 *Clin Med* 2021; 10(8)

409 2. Cummings MJ, Baldwin MR, Abrams D, et al: Epidemiology, clinical course, and outcomes of

410 critically ill adults with COVID-19 in New York City: a prospective cohort study. *Lancet* 2020;

411 395(10239):1763-1770

412 3. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised,
413 controlled, open-label, platform trial. *Lancet* 2021; 397(10285):1637-1645

414 4. Datta SD, Talwar A, Lee JT: A Proposed Framework and Timeline of the Spectrum of Disease

415 Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public Health Implications. JAMA

416 2020; 324(22):2251-2252

417 5. Cevik M, Kuppalli K, Kindrachuk J, et al: Virology, transmission, and pathogenesis of SARS418 CoV-2. *Bmj* 2020; 371:m3862

419 6. Nicolau M, Levine AJ, Carlsson G: Topology based data analysis identifies a subgroup of breast

420 cancers with a unique mutational profile and excellent survival. *Proc Natl Acad Sci U S A* 2011;

421 108(17):7265-7270

- 422 7. Singh G, Mémoli F, Carlsson GE: Topological methods for the analysis of high dimensional data
- 423 sets and 3d object recognition. *PBG@ Eurographics* 2007; 2
- 424 8. Shoemark A, Rubbo B, Legendre M, et al: Topological data analysis reveals genotype-phenotype
- 425 relationships in primary ciliary dyskinesia. *Eur Respir J* 2021; 58(2)
- 426 9. Bruno JL, Romano D, Mazaika P, et al: Longitudinal identification of clinically distinct
- 427 neurophenotypes in young children with fragile X syndrome. *Proceedings of the National Academy of*
- 428 Sciences 2017; 114(40):10767-10772
- 429 10. Krishnan S, Beckett C, Espinosa B, et al: Austere environments Consortium for Enhanced Sepsis
- 430 Outcomes (ACESO). Shock (Augusta, Ga) 2020; 53(3):377-378
- 431 11. Cihakova D, Streiff MB, Menez SP, et al: High-value laboratory testing for hospitalized COVID-
- 432 19 patients: a review. *Future Virol* 2021
- 433 12. Laing E, Sterling S, Richard S, et al: A betacoronavirus multiplex microsphere immunoassay
- 434 detects early SARS-CoV-2 seroconversion and antibody cross reactions. *Res Sq* 2020
- 435 13. Richard SA, Pollett SD, Lanteri CA, et al: COVID-19 outcomes among U.S. Military Health
- 436 System beneficiaries include complications across multiple organ systems and substantial functional
- 437 impairment. Open Forum Infectious Diseases 2021
- 438 14. Gustine JN, Jones D: Immunopathology of Hyperinflammation in COVID-19. *Am J Pathol* 2021;
 439 191(1):4-17
- 440 15. Lucas C, Wong P, Klein J, et al: Longitudinal analyses reveal immunological misfiring in severe
 441 COVID-19. *Nature* 2020
- 16. Rozo M, Schully KL, Philipson C, et al: An Observational Study of Sepsis in Takeo Province
- 443 Cambodia: An in-depth examination of pathogens causing severe infections. *PLoS Negl Trop Dis* 2020;
- 444 14(8):e0008381
- 445 17. Leek JT, Johnson WE, Parker HS, et al: The sva package for removing batch effects and other
- 446 unwanted variation in high-throughput experiments. *Bioinformatics* 2012; 28(6):882-883

- 447 18. Epsi NJ, Panja S, Pine SR, et al: pathCHEMO, a generalizable computational framework
- uncovers molecular pathways of chemoresistance in lung adenocarcinoma. *Communications Biology*2019; 2(1):334
- 450 19. Ayasdi. Available at: <u>https://www.ayasdi.com/enterprise-ai/platform/</u>. Accessed
- 451 20. Lum PY, Singh G, Lehman A, et al: Extracting insights from the shape of complex data using
- 452 topology. *Sci Rep* 2013; 3:1236
- 453 21. Team TRDC: R: A language environment for statistical computing. R Foundation for Statistical
 454 Computing. 2020
- 455 22. Karaba AH, Zhou W, Hsieh LL, et al: Differential Cytokine Signatures of SARS-CoV-2 and
- 456 Influenza Infection Highlight Key Differences in Pathobiology. *Clin Infect Dis* 2021
- 457 23. van der Made CI, Simons A, Schuurs-Hoeijmakers J, et al: Presence of Genetic Variants Among
- 458 Young Men With Severe COVID-19. *Jama* 2020; 324(7):663-673
- 459 24. Asano T, Boisson B, Onodi F, et al: X-linked recessive TLR7 deficiency in ~1% of men under 60
- 460 years old with life-threatening COVID-19. *Sci Immunol* 2021; 6(62)
- 461 25. Takahashi T, Ellingson MK, Wong P, et al: Sex differences in immune responses that underlie
- 462 COVID-19 disease outcomes. *Nature* 2020; 588(7837):315-320
- 463 26. Griffiths MJD, McAuley DF: RAGE: a biomarker for acute lung injury. *Thorax* 2008;
- **464** 63(12):1034-1036
- 465 27. Lim A, Radujkovic A, Weigand MA, et al: Soluble receptor for advanced glycation end products
- 466 (sRAGE) as a biomarker of COVID-19 disease severity and indicator of the need for mechanical
- 467 ventilation, ARDS and mortality. Ann Intensive Care 2021; 11(1):50
- 468 28. Abers MS, Delmonte OM, Ricotta EE, et al: An immune-based biomarker signature is associated
- 469 with mortality in COVID-19 patients. JCI Insight 2021; 6(1)
- 470 29. Bucciarelli LG, Kaneko M, Ananthakrishnan R, et al: Receptor for advanced-glycation end
- 471 products: key modulator of myocardial ischemic injury. *Circulation* 2006; 113(9):1226-1234

472 30. Wendt T, Harja E, Bucciarelli L, et al: RAGE modulates vascular inflammation and

473 atherosclerosis in a murine model of type 2 diabetes. *Atherosclerosis* 2006; 185(1):70-77

474 31. Harja E, Bu DX, Hudson BI, et al: Vascular and inflammatory stresses mediate atherosclerosis

475 via RAGE and its ligands in apoE-/- mice. J Clin Invest 2008; 118(1):183-194

476

477 Figure legends.

478 Figure 1. Topological data analysis (TDA) network of protein expression during the middle-phase of

479 COVID-19. Distinct protein expression phenotypes (Clusters 1, 2, and 3) were identified based on density

480 and break points in the network and persistence of the clusters. Each node represents a combination of 12

481 plasma protein analyte levels and its size increases with the number of participants that are included.

482 Edges (lines between nodes) indicate that patients are represented in more than one node. The network is

483 colored by the average score on the disease severity scale (from outpatients without limitations [green] to

death [red]) in each node. Analysis was performed on the EurekaAI Workbench (SymphonyAI, Los

485 Altos, CA, USA).

486

Figure 2. Cluster differences with bar plots (% [n]) of comorbid diseases and severity by cluster. A: BMI
(body mass index) category (range in kg/m²) prevalence by cluster; B: Charlson Comorbidity Index (CCI)
category prevalence by cluster; C: peak levels of severity by cluster. Total (n) presented in the center of
each category.

491

492 Figure 3. Box plots of markers selected in stepwise regression to identify characteristic biomarkers of 493 each cluster: Ferritin (A), IL1RA (B), RAGE (C), and VEGFA (D) by cluster. Kruskal-Wallis test 494 performed comparing analyte levels between clusters. **: $p \le 0.01$; ***: $p \le 0.001$; ****: $p \le 0.0001$ 495



















Characteristic	Total (N=129)	Cluster 1 (N=50)	Cluster 2 (N=64)	Cluster 3 (N=15)	p-value
Male gender — no. (%)	86(66.7%)	31(62%)	41(64.1%)	14(93.3%)	0.06†
Age — years, median (IQR)	41.3 (30.1, 56)	51.8 (37.3, 65)	37.1 (28.05, 49.55)	36.3 (24.6, 55.2)	<0.001‡
Race or ethnic group — no. (%)					0.01†
White	81 (62.8)	30 (60.0)	43 (67.2)	8 (53.3)	
Black	31 (24.0)	16 (32.0)	12 (18.8)	3 (20.0)	
Other	6 (4.7)	1 (2.0)	5 (7.8)	2 (13.3)	
Asian	5 (3.9)	0 (0)	3 (4.7)	2 (13.3)	
Native American	3 (2.3)	0 (0)	1 (1.6)	0 (0)	
Native Hawaiian	3 (2.3)	3 (6.0)	0 (0)	0 (0)	
Ethnicity — no. (%)					0.88^{+}
Hispanic or Latinx	31(24)	13(26)	15(23.4)	3(20)	
Charlson Comorbidity Index (CCI) — median (IQR)	0 (0, 2)	2 (2, 3)	0 (0, 0.5)	0 (0, 1)	0.009 †
Body mass index — kg/m², median (IQR)	30 (27, 34)	33.5 (29, 37)	28 (25, 31)	28 (25, 31)	<0.001‡
Days post-symptom onset — median (IQR)	21.0 (18.0, 25.0)	20 (17.0, 25.0)	21.0 (19.0, 25.5)	22.0 (21.0, 25.0)	0.16 †
Hospitalization at Timepoint — no. (%)					<0.001
ICU	10(7.8)	9(18)	1(1.6)	0	
Inpatient	28(21.7)	16(32)	7(10.9)	5(33.3)	
Outpatient	91(70.5)	25(50)	56(87.5)	10(66.7)	
Peak severity — no. (%)					<0.001
Death	5 (3.9)	5 (10.0)	0 (0)	0 (0)	
ICU	16 (12.4)	10 (20.0)	3 (4.7)	3 (20.0)	
Inpatient	31 (24.0)	18 (36.0)	9 (14.1)	4 (26.7)	
Outpatient	77 (59.7)	17 (34.0)	52 (81.3)	8 (53.3)	
Systemic Steroid use — no. (%)	5 (3.9)	5 (10.0)	0 (0)	0 (0)	

 Table 1. Baseline demographics across TDA clusters.

*All categorical variables are presented as N(%) and continuous variable

† Chi-square test

‡ Mann Whitney U test
Fischer's Exact test

Plasma log ₁₀ pg/mg, median (IQR)					
Variable	Total	Cluster 1	Cluster 2	Cluster 3	p-value*
CRP	6.75 (6.09, 7.62)	7.33 (6.67, 7.98)	6.43 (5.89, 7.11)	6.29 (5.68, 7.13)	<0.001
CXCL10	2.17 (1.95, 2.37)	2.28 (1.94, 2.53)	2.1 (1.88, 2.28)	2.19 (2.09, 2.51)	0.02
D-dimer	5.69 (5.34, 6.23)	6.06 (5.68, 6.85)	5.49 (5.27, 5.87)	5.68 (5.3, 6.52)	<0.001
Ferritin	5.3 (4.98, 5.65)	5.46 (5.07, 5.87)	5.17 (4.82, 5.37)	5.51 (5.31, 5.9)	<0.001
ΙΓΝγ	-0.25 (-0.45, 0)	-0.3 (-0.58, 0)	-0.21 (-0.39, 0)	-0.27 (-0.46, 0.02)	0.11
IL1Ra	2.85 (2.56, 3.11)	3.01 (2.84, 3.37)	2.67 (2.5, 2.97)	2.69 (2.4, 2.92)	<0.001
IL5	-0.56 (-0.86, 0.34)	-0.57 (-0.95, -0.4)	-0.57 (-0.81, - 0.31)	-0.51 (-0.85, -0.24)	0.69
IL6	0.26 (0.01, 0.63)	0.52 (0.24, 1.1)	0.07 (-0.13, 0.43)	0.26 (0.05, 0.6)	<0.001
Procalcitonin	1.78 (1.63, 2)	1.92 (1.7, 2.25)	1.69 (1.59, 1.86)	1.92 (1.77, 2.1)	<0.001
RAGE	2.93 (2.78, 3.04)	2.76 (2.58, 2.87)	3.02 (2.92, 3.09)	3 (2.8, 3.07)	<0.001
TNFR1	3.03 (2.95, 3.18)	3.15 (3.01, 3.3)	2.98 (2.91, 3.08)	3.04 (2.97, 3.16)	<0.001
VEGFA	1.64 (1.43, 1.92)	1.9 (1.57, 2.12)	1.58 (1.43, 1.76)	1.25 (0.8, 1.52)	<0.001

Table 2. Comparison of the Ella biomarkers across TDA clusters. For each subject, one sample was selected based on highest coefficient of variation.

*Distributions among all clusters compared using a Kruskal-Wallis test.